Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

144 results about "Low glucose" patented technology

Bolus permissions and prioritization scheme for infusion pump system

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.
Owner:TANDEM DIABETES CARE INC

3D printed bone defect repair scaffold loaded with extracellular matrix of mesenchymal stem cells and preparation method thereof

A 3D printed bone defect repair scaffold loaded with extracellular matrix of mesenchymal stem cells is provided, its preparation method includes: dissolving gelatin, sodium alginate and 58S bioglass in water to obtain a solution, stirring the solution evenly to obtain 3D printing slurry, and performing 3D printing; chemically cross-linking the semi-finished scaffold with a calcium chloride solution, followed by soaking in a glutaraldehyde solution to chemically cross-link, and cleaning and freeze-drying to obtain the 3D printed scaffold; sterilizing the 3D printed scaffold; seeding rBMSC suspension on the sterilized 3D printed scaffold at a concentration of at least 106 cells / well, and culturing rBMSC by using a low glucose DMEM with 10% FBS for 2 weeks; and taking out the scaffold to perform a decellularization treatment, and freeze-drying the decellularized 3D printed scaffold to obtain the 3D printed bone defect repair scaffold loaded with extracellular matrix of mesenchymal stem cells.
Owner:HOSPITAL OF STOMATOLOGY GUANGZHOU MEDICAL UNIVERSITY (YANGCHENG HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY)

High-stability oat milk beverage and preparation method thereof

The invention discloses a high-stability oat milk beverage and a preparation method thereof, and belongs to the technical field of grain deep processing. The preparation method of the oat milk beverage comprises the following steps: cleaning and drying oat to obtain dry oat, adding water, grinding into thick liquid, and boiling and gelatinizing to obtain gelatinized liquid; adding alpha-amylase, debranching enzyme, saccharifying enzyme and neutral protease into the gelatinized liquid, stirring, performing enzymolysis, performing enzyme deactivation, sieving, and collecting slurry; and finally homogenizing to obtain the oat milk. According to the preparation method disclosed by the invention, the stability of the oat milk is improved by optimizing process conditions and enzymes used for enzymolysis in the preparation of the oat milk, the preparation of the functional oat milk is realized by further adding functional components under the condition that the stability of the oat milk is not influenced, and the prepared oat milk can realize various effects of reducing blood sugar, resisting fatigue and the like.
Owner:NINGBO UNIV +2

Activity mode for artificial pancreas system

A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and / or a detected location of the user.
Owner:INSULET CORP

Enterococcus faecalis EF-1 capable of reducing blood lipid, microbial preparation and application of enterococcus faecalis EF-1

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.
Owner:FEED RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Drug for reducing blood glucose and / or treating diabetic complications

Disclosed is a drug for lowing blood glucose and / or improving diabetic complications, belonging to the technical field of biomedicine. According to the present disclosure, the drug for lowing blood glucose and / or improving diabetic complications is nanoparticles formed by a component containing lipoic acid and / or lipoic acid derivatives. The lipoic acid nanoparticles not only can control blood glucose safely and long-term, but also can realize the prevention / treatment of diabetic complications through lowering blood glucose and inhibiting oxidative stress. This drug has good clinical prospect.
Owner:CHENGDU DELLON BIOMEDICINE CO LTD

Glucose-responsive molecular connector, and preparation method therefor and use thereof

Provided in the present invention is a glucose-responsive molecular connector, and a preparation method therefor and the use thereof. A brand-new glucose-responsive molecular connector is formed by the esterification of a phenylboronic acid analogue and a 1,3-diol structure. The compound can be directly biolinked to insulin by amidation and has a very good glucose-responsive function, wherein glucose at a high concentration competes with the 1,3-diol structure for binding to phenylboronic acid, so that the solubility of insulin is increased and the release of insulin is promoted, and when the glucose is at a low concentration, only a small amount of insulin is in a free state, thereby reducing the occurrence of hypoglycemia. The compound achieves the glucose response of insulin by means of a brand-new mechanism, causing the glucose response effect more sensitive. Moreover, the compound has the advantages of simple structure, being easy to prepare and low cost, and has great clinical application value.
Owner:ZHEJIANG UNIV

Use of carbohydrate-containing compositions in tablet form for treatment of hypoglycemic states

PCT designated stage expiredWO2024252015A1Metabolism disorderCoatingsLow glucoseNocturnal hypoglycemia
The invention relates to the use of specific carbohydrate-containing compositions, in particular in tablet form, for production of agents for treatment of hypoglycemia, in particular nocturnal hypoglycemia. The compositions are easy to dose and do not leave a sweet taste in the mouth, but do release the carbohydrates present rapidly in the stomach and are therefore particularly suitable for treatment of in particular nocturnal hypoglycemia.
Owner:EUVORIO GMBH

Method, system and computer readable medium for assessing actionable glycemic risk

A system, method and non-transient computer readable medium for assessing the opportunity to address either hyperglycemic or hypoglycemic risk (or both) in patients with diabetes based on historical continuous glucose monitoring (CGM) data.
Owner:UNIV OF VIRGINIA PATENT FOUND

Non-invasive monitoring system

A wearable device for non-invasive monitoring of the presence, amount, and / or concentration of an analyte in a sample from a user of the device is described. The analyte is selected to be indicative of or related to a physiological status of a user. Relevant physiological status include hypoglycemia, infection, respiratory infection, urinary infection, gastrointestinal infection, obesity, diabetes, type I diabetes and type II diabetes.
Owner:AERBETIC INC

Cinnamon fine dried noodles with low glycemic index and preparation method thereof

The invention provides cinnamon fine dried noodles with a low glycemic index and a preparation method of the cinnamon fine dried noodles, and belongs to the technical field of food processing. The low-GI cinnamon fine dried noodles provided by the invention are prepared from the following raw materials in parts by weight: 100 to 120 parts of flour, 0.5 to 2.5 parts of cinnamon active extract, 1.0 to 2.0 parts of table salt, 0.2 to 1.0 part of dietary alkali and 35 to 55 parts of water. By adding the cinnamon active extract, the nutritional value of traditional wheat fine dried noodles is considered, and the advantages of low-GI food are achieved. While the addition amount of the flour is not reduced, the flavor of the fine dried noodles is enriched, and the hypoglycemic health-care function of the fine dried noodles is also improved.
Owner:GUANGXI UNIV OF CHINESE MEDICINE +1

Timing and dosing improvements for diabetes management

In an embodiment, a system for of preventively treating hypoglycemia includes a continuous glucose monitoring (CGM) sensor system configured to generate measurements associated with a current glucose level of a patient. The system further includes one or more memories comprising executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive, from the CGM sensor system, one or more measurements associated with the current glucose level of the patient and compute a sequence of preventive hypoglycemia treatments over a future time period based on the one or more measurements and a prediction of glucose control to be produced by the sequence. The one or more processors are further configured to prompt the patient with a first preventive hypoglycemia treatment in the sequence of preventive hypoglycemia treatments.
Owner:DEXCOM INC

Glucose slow-release structure used in embryo in-vitro culture solution as well as preparation process and use method of glucose slow-release structure

The invention belongs to the technical field of assisted reproduction, and particularly relates to a glucose slow-release structure used in an embryo in-vitro culture solution, a preparation process and a use method. The glucose slow-release structure comprises at least one inner layer containing glucose and a biodegradable material outer layer wrapping the inner layer, and the biodegradable material outer layer comprises a matrix with a plurality of micropores and at least one sealing material layer used for sealing pores of the micropores. According to the invention, gradient release from low sugar in the cleavage stage to high sugar in the blastocyst stage is realized, midway liquid change or artificial sugar supplement is not needed, the operation is obviously simplified, and pollution and mechanical stress risks are reduced.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Readily soluble and thermostable glucagon formulations and delivery for mini-dosing and closed -loop prophylactic treatment of hypoglycemia

PendingUS20250025411A1Peptide/protein ingredientsOxidoreductasesLow glucoseGlucagon preparation
Insulin therapy revolutionized the care of patients with diabetes, yet insulin-induced hypoglycemia remains a serious life-threatening complication of insulin therapy. Glucagon is a highly effective treatment for hypoglycemia; however, current dosage forms remain under-utilized due to poor patient compliance. High-density, readily soluble, and thermostable solid glucagon formulations applied with painless, application-specific microneedle-patches can treat hypoglycemia in type 1 diabetes patients who are awake or asleep. On-demand patches can prevent or treat mild hypoglycemia during the day, and enzyme-driven hypoglycemia-responsive patches can release glucagon autonomously during the night. These patches have excellent in vitro glucagon stability, loading, and release kinetics and can treat hypoglycemia in diabetic humans and animals. These delivery systems enable new modes of glucagon therapy, thereby expanding the clinical role of glucagon beyond the emergency setting.
Owner:MASSACHUSETTS INST OF TECH +1

Low Glycemic Index (Gi) Total Nutrition Formula Milk And Preparation Method Therefor

PendingUS20250228281A1Food scienceLow glucosePhysiology
The present invention provides low glycemic index (GI) total nutrition formula emulsion and a preparation method therefor. The low GI total nutrition formula emulsion comprises the following raw material components in parts by weight: 10-14 parts of carbohydrates, 4-5 parts of calcium caseinate, 1.3-2 parts of dietary fiber, 0.1-0.15 part of sodium chloride, 0.1-0.12 part of sodium citrate, 0.1-0.15 part of potassium citrate, 0.15-0.2 part of magnesium chloride, 0.1-0.15 part of dipotassium hydrogen phosphate, 0.05-0.1 part of compound vitamins, 0.05-0.1 part of compound minerals, 2.5-3.6 parts of compound oil, 0.3-0.5 part of phospholipid, 0.2-0.5 part of medium chain triglyceride (MCT), 0.04-0.08 part of colloids. The preparation method comprises: preparing aqueous phases and oil phases from the raw materials step by step; mixing the aqueous phases and oil phases; and shearing, homogenizing and sterilizing the mixture to obtain the low GI total nutrition emulsion. The product features balanced and complete nutrition.
Owner:CHINA NAT RES INST OF FOOD & FERMENTATION IND CO LTD

Formulations for improving sweetness of rare sugars without altering texture and flavor and methods thereof

Disclosed herein are formulations (including sweet proteins and rare sugars) for improving the sweetness of low glycemic index rare sugars without altering the texture and flavor of the rare sugars and methods for improving the sweetness of rare sugars. More specifically, the present invention discloses methods for improving the sweetness of rare sugars without altering the sweetness profile, texture and flavor of the primary sugars. The invention also discloses the addition of Brazitame protein with liquid rare sugars at different temperatures during the synthesis of the rare sugars, before crystallization or before or after caramelization of the rare sugars, to increase sweetness. The Brazilian sweet protein increases the sweetness of rare sugars, but is not limited to D-psicose, D-tagatose, D-allose, isomaltulose, trehalose, sorbose, pinose, leucobiose and the like. The invention also provides for the evaluation of non-nutritional sweeteners (such as aspartame, acesulfame, sodium cyclamate, neotame, saccharin, sucralose, stevioside, etc.), as each has a limitation of taste quality if used with rare sugars. However, the use of Brazilian sweet protein does not alter the flavor and texture of rare sugars, and the taste profile matches sucrose.
Owner:FORTIS INDIA PTE LTD

Low-GI high-fiber wholewheat biscuit and preparation method thereof

The invention belongs to the technical field of food processing, particularly relates to a low-GI high-fiber wholewheat biscuit and a preparation method thereof, and further relates to application of the low-GI high-fiber wholewheat biscuit as a low-glycemic-index food to regulation of intestinal flora. The soluble dietary fiber inulin is added into the whole wheat flour, the processing characteristics of the whole wheat flour and dough are remarkably improved through the addition of the inulin, the color and luster of the biscuit are also remarkably improved, the prepared low-GI high-fiber whole wheat biscuit has good taste and good crispness, and the content of total dietary fibers in the biscuit is as high as 19%. The GL value of the low-GI high-fiber whole-wheat biscuit is only 8.20, the GI value is 50.24, the GL value and the GI value are obviously lower than those of whole-wheat biscuits, and the low-GI high-fiber whole-wheat biscuit belongs to low-blood-sugar-load food and has a better adjusting effect on intestinal flora and short-chain fatty acid compared with the whole-wheat biscuits.
Owner:SHANDONG ACADEMY OF AGRICULTURAL SCIENCES

Glucose control using digital twin metabolic models

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.
Owner:OREGON HEALTH & SCI UNIV

(Z)-5-hydroxy-3-methyl-pent-2-enamide and application thereof

The invention relates to (Z)-5-hydroxy-3-methyl-pent-2-enamide and application thereof, in particular to a novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide extracted and separated from secondary metabolites of Fusarium acuminatum, the novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide is white powder, the molecular formula of the novel compound (Z)-5-hydroxy-3-methyl-pent-2-enamide is C6H11NO2, and a quasi-molecular ion peak given by a high-resolution mass spectrum is [2M + Na-CO] + 253.1543; the invention relates to an application of (Z)-5-hydroxy-3-methyl-pent-2-enamide in preparation of a medicine for reducing blood sugar, in particular to an application of (Z)-5-hydroxy-3-methyl-pent-2-enamide.
Owner:HARBIN UNIV OF COMMERCE

Particle structure of peptides extracted from Murray cod

The particle structure of Murray cod extract peptides is provided. [Solution] The particle structure 1 of the Murray cod extract peptide is mainly a spherical structure, and the inside of the spherical structure contains a Murray cod extract peptide layer 10, and the carrier 20 is located on the outer layer of the Murray cod extract peptide layer and covers the Murray cod extract peptide layer. It can be taken orally or wiped externally, and can prevent kidney stones, help glucose metabolism, relieve hypoglycemia, and improve body energy. Murray cod extract peptide is one of the energy sources for muscle tissue and the brain central nervous system, and can help the production of antibodies and aid the metabolism of carbohydrates and organic acids.
Owner:TAIWAN GOODWILL MURRAY PEPTIDE TECHNOLOGIES LNC

A low glycemic index health drink rich in monk fruit flavonoids and its preparation method

This invention relates to the field of beverage technology, specifically disclosing a low glycemic index health beverage rich in monk fruit leaf flavonoids. The beverage comprises main ingredients, which are composed of the following components by weight: 18-35 parts monk fruit leaf extract, 15-22 parts bitter melon extract, and 15-22 parts houttuynia cordata extract. This invention's low glycemic index health beverage, rich in monk fruit leaf flavonoids, utilizes the bioactivity of natural plant raw materials such as monk fruit leaves, bitter melon, and houttuynia cordata. Through a reasonable proportion of components, it is formulated into a compound beverage with high nutritional value, possessing health benefits such as anti-fatigue, antipyretic, anti-inflammatory, diuretic, and non-toxic effects. Furthermore, it is safe and non-toxic. Combined with monk fruit glycosides and erythritol as sweeteners, it has a good flavor while maintaining a low glycemic index, meeting the needs of people trying to reduce their sugar intake.
Owner:GUILIN SHILI SCI & TECH COMPANY

Starch gel and preparation method thereof

The invention relates to the field of food processing, and discloses starch gel and a preparation method thereof. The method comprises the following steps: mixing starch and water-soluble hemicellulose to obtain a mixed solution, and carrying out heat treatment on the mixed solution; wherein the mass ratio of the starch to the water-soluble hemicellulose is (8-15): 1; wherein in the starch, the mass of amylose accounts for more than 60wt% of the total mass of the starch. After the food containing the starch gel provided by the invention is eaten, the starch digestibility is obviously lower, the blood sugar rising degree is lower, and the starch gel provided by the invention is healthier and more suitable for being applied to food production.
Owner:JILIN COFCO BIOCHEM +2

Hericium erinaceus hypoglycemic peptide as well as preparation method and application thereof

The invention discloses hericium erinaceus hypoglycemic peptide as well as a preparation method and application thereof. The amino acid sequence of the hericium erinaceus hypoglycemic peptide is GRVVPAPIPR. Polypeptides are extracted and purified from hericium erinaceus sporocarp protein, an amino acid sequence of one of the peptides for reducing blood sugar is determined through LC-MS / MS, the inhibition rate of the peptide for alpha-amylase is 80.63% + / -0.23% through blood sugar reduction activity detection, the inhibition rate of the peptide for alpha-glucosidase is 70.77% + / -0.29%, the peptide can be used as a natural peptide for reducing blood sugar, and the peptide for reducing blood sugar can be used as a natural peptide for reducing blood sugar. Potential application prospects are realized in the fields of preparation of medicines for reducing blood sugar and the like.
Owner:SHANGHAI ACAD OF AGRI SCI

Production method for increasing yield of maltose

The invention provides a production method for increasing the yield of maltose, which comprises the following steps: proportioning, liquefying and saccharifying, controlling the concentration of starch milk through proportioning, reducing the concentration of syrup, improving the flowability of a system, obtaining a liquefied liquid with a low DE value in the liquefying process, and simultaneously adjusting the pH values of different reaction steps, so that the yield of maltose is increased. Finally, after saccharification is completed, the ultrahigh malt syrup which is low in content of glucose, maltose trisaccharide, maltose trisaccharide or more and high in maltose content is obtained, and the highest maltose content can reach 93%.
Owner:NINGXIA JINMEIYINO ANIMAL BEVERAGE CO LTD

Sugar-responsive molecular connector as well as preparation method and application thereof

According to the sugar-responsive molecular connector and the preparation method and application thereof provided by the invention, a brand new sugar-responsive molecular connector compound is formed by esterification and combination of a phenylboronic acid analogue and a 1, 3-diol structure, and the compound can be directly biologically linked with insulin through amidation and has a very good glucose-responsive function; high-concentration glucose can be competitively combined with a 1, 3-diol structure and phenylboronic acid, so that the solubility of insulin is increased, and the release of insulin is promoted; when the concentration is low, only a small part of insulin is in a free state, so that the occurrence of hypoglycemia is reduced. The compound utilizes a brand new mechanism to realize sugar response of insulin, so that the sugar response effect is more sensitive, and the compound is simple in structure, easy to prepare, low in cost and extremely high in clinical application value.
Owner:ZHEJIANG UNIV

Prebiotic soft fried dough twist and making method thereof

The invention discloses prebiotic soft fried dough twists and a making method thereof, and belongs to the technical field of food. The fried dough twist disclosed by the invention is prepared from the following raw materials in parts by mass: 132 to 169.5 parts of a dough base material, 5 to 6 parts of resistant dextrin, 7 to 9 parts of fructo-oligosaccharide microcapsules, 6 to 8 parts of isomaltitol, 1.5 to 2 parts of stachyose, 0.5 to 1.0 part of soybean lecithin and 0.01 to 0.03 part of vitamin E. The prebiotic retention rate is synergistically increased through microcapsule coating and a making process, the aging resistance of the fried dough twist is improved through synergistic moisturizing of resistant dextrin and fructo-oligosaccharide microcapsules, white granulated sugar is partially replaced by isomaltitol, stachyose and other sugar parts with low glycemic index, and the taste of the fried dough twist is improved. And the resistant dextrin with high dietary fiber content and the fructo-oligosaccharide prebiotics are matched, so that the product not only meets the sweet taste requirement, but also meets the healthy diet pursuit of modern consumers on low sugar, high fiber and high prebiotics.
Owner:SHANDONG BAILONG CHUANGYUAN BIO TECH CO LTD

Low-glycemic-index hericium mushroom steamed buns and preparation method thereof

PendingCN122271470ABiotechnologyAmylase
This invention discloses a low glycemic index (GI) Hericium erinaceus (monkey head mushroom) steamed bun, belonging to the field of food processing and functional food applications. By weight, it is prepared from the following raw materials: 45-55 parts all-purpose flour, 28-35 parts Hericium erinaceus extract powder, 0.3-0.35 parts yeast, 15-18 parts water, 0.3-0.6 parts oil, and 0.7-0.9 parts sugar. This invention partially replaces the flour with Hericium erinaceus extract powder, fully utilizing the multiple mechanisms of action of Hericium erinaceus polysaccharides in forming a viscous gel in the digestive tract to slow down the contact between amylase and substrate, inhibiting α-amylase and α-glucosidase activity, and improving intestinal microecology and enhancing insulin sensitivity through dietary fiber. This allows the product to meet the low-GI food standard (GI<55), effectively filling the gap in low-GI steamed buns with Hericium erinaceus functional components as the core active ingredient. It has significant application value in the fields of diabetes management, weight control, and healthy staple foods.
Owner:ZHEJIANG UNIV OF TECH +1

Lactobacillus acidophilus goldgut-la100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.
Owner:SHENZHEN PORSHEALTH BIOENGINEERING CO LTD

Use of polypeptide in preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof

Disclosed is use of a polypeptide in the preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof, which belongs to the technical field of biological medicines. The polypeptide is a human GPR15L polypeptide or a mouse GPR15L polypeptide and a polypeptide conjugate thereof. The treatment of obesity includes: reducing fat accumulation, promoting fat thermogenesis and catabolism, increasing energy consumption, and reducing body weight. The obesity comorbidities include: chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors, and skin diseases. A novel mechanism of action reduces blood glucose and body weight, thereby effectively treating obesity and comorbidities thereof.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Healthy sweetener

Food and / or beverage additives are generally provided. In some embodiments, the additive comprises a sweetener (e.g., a healthy sweetener). The additives and / or sweeteners described herein may be useful when added a food and / or beverage e.g., to increase the sweetness of a food and / or beverage. In some embodiments, the additives and / or sweeteners may advantageously be used to reduce the sugar and / or caloric content of a food and / or beverage e.g., as compared to the food and / or beverage without the additive and / or sweetener or containing conventional sweeteners. Advantageously, the additives comprising the sweeteners described herein may be useful for providing a food and / or beverage having a relatively low glycemic index and / or a relatively low number of calories per serving.
Owner:SUGAR LICENSE LLC